Daily Respiratory Research Analysis
Analyzed 222 papers and selected 3 impactful papers.
Summary
Three impactful studies span prevention, epidemiology, and critical care in respiratory medicine. Real-world rollout of nirsevimab in Italy averted pediatric RSV hospitalizations and was largely cost-saving. A Danish nationwide cohort linked combustion-related pollutants (black carbon and NO2) to adult-onset asthma and COPD, while a post hoc analysis showed prophylactic NIV plus HFNC reduces reintubation after extubation in high-risk, non-hypercapnic patients.
Research Themes
- RSV immunoprophylaxis effectiveness and economics
- Combustion-related air pollution and chronic respiratory disease risk
- Post-extubation noninvasive ventilation strategies in ICU
Selected Articles
1. Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations.
Across 19 Italian pediatric centers, nirsevimab immunization reduced RSV hospitalizations compared with modeled counterfactuals and was cost-saving from the health system perspective in most centers. Admissions averted ranged from 6 to 151 per center (83–1162 per 100,000 children), with negative incremental costs in most sites; late and restricted rollouts were less cost-effective.
Impact: Provides robust real-world evidence that early, broad nirsevimab rollout averts hospitalizations and saves costs, informing policy and program scale-up for RSV prevention.
Clinical Implications: Health systems should prioritize early-season, broad-eligibility nirsevimab campaigns to maximize admissions averted and cost savings; centers with delayed or narrow rollout may see diminished value.
Key Findings
- Observed RSV admissions were lower than counterfactual predictions in most of 19 centers during 2024–2025.
- Immunization averted 6–151 admissions per center (83–1162 per 100,000 children).
- Incremental costs were negative (cost-saving) in most centers (e.g., −€10,924 to −€266,954); two centers with late/restricted rollout had positive incremental costs.
- Sensitivity analyses supported robustness of effectiveness and economic findings.
Methodological Strengths
- Multicenter real-world analysis across 19 hospitals in 11 regions, improving generalizability.
- Use of center-specific Poisson counterfactual models and payer-perspective costing to estimate admissions averted and incremental costs.
Limitations
- Observational design with potential residual confounding and heterogeneous rollout timing/eligibility.
- Center-level analysis may lack individual vaccination status linkage; generalizability to other health systems may vary.
Future Directions: Link individual-level immunization records to outcomes, assess equity of access, and compare alternative rollout strategies and pricing scenarios across diverse health systems.
IMPORTANCE: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and young children, imposing a substantial burden on health care systems. Nirsevimab, a long-acting monoclonal antibody, has shown high efficacy in clinical trials, and modeling studies suggest it may be cost-effective; however, real-world evidence on its cost-effectiveness in European health care settings remains limited. OBJECTIVE: To evaluate the real-world cost-effectiveness of nirsevimab immunization in preventing pediatric hospitalizations due to RSV. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, observational, real-world cost-effectiveness analysis was conducted between October 1, 2022, and March 31, 2025. Precampaign data were modeled using Poisson regression models to estimate expected hospitalizations in the absence of immunization. Data were gathered from 19 pediatric hospitals distributed across 11 Italian regions, from northern to southern areas. Included were all pediatric hospitalizations with RSV-specific International Classification of Diseases, Ninth Revision, Clinical Modification discharge diagnoses recorded at participating hospitals between October 1, 2022, and March 31, 2025.
2. Long-term exposure to air pollution and risk of adult-onset asthma and COPD: Danish nationwide cohort study.
Among 3.2 million adults with up to 19 years of follow-up, interquartile increases in NO2 and BC were robustly associated with higher incidence of adult-onset asthma (HR 1.16 and 1.17) and COPD (HR 1.05 and 1.06). PM2.5 associations attenuated to null after adjusting for NO2/BC, implicating combustion-related pollutants as key drivers.
Impact: Defines black carbon and NO2 as dominant predictors of adult-onset asthma/COPD in a massive nationwide cohort, sharpening targets for air-quality policy beyond PM2.5 mass.
Clinical Implications: Counseling and public health policies should prioritize reduction of combustion-related emissions (traffic, heating) to curb adult-onset asthma/COPD; clinicians can incorporate location-specific exposure risk into prevention strategies.
Key Findings
- Per IQR increase, NO2 and BC were associated with asthma incidence (HR 1.16 [1.13–1.19] and 1.17 [1.14–1.20]) and COPD incidence (HR 1.05 [1.03–1.07] and 1.06 [1.04–1.08]).
- PM2.5 associations attenuated to null after adjustment for NO2/BC, while NO2/BC remained robust when adjusted for PM2.5.
- Similar patterns were observed for first OAD medication prescriptions (asthma/COPD combined incidence).
Methodological Strengths
- Nationwide cohort of 3.2 million adults with up to 19 years of follow-up and extensive adjustment including smoking and BMI.
- Exposure assignment via European hybrid land-use regression models for PM2.5, NO2, and BC; multipollutant modeling.
Limitations
- Outcomes based on first hospital contact may miss primary care–managed cases; residual confounding cannot be excluded.
- Exposure misclassification at individual level (residential proxies) is possible.
Future Directions: Source-specific interventions (traffic, residential heating) and personal exposure studies; refine BC metrics and mechanistic links to airway inflammation and remodeling.
RATIONALE: Long-term exposure to air pollution contributes to chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). While the effect of fine particulate matter (PM2.5) and nitrogen dioxide (NO2) are supported by evidence, the contribution of black carbon (BC), a combustion-related pollutant, remains unclear. OBJECTIVES: To investigate associations of long-term exposure to BC as well as PM2.5 and NO2 with incidence of adult-onset asthma and COPD in Denmark. METHODS: We followed 3.2 million Danish residents aged 30 years or older on January 1, 2000 until December 31, 2018, for incidence of asthma and COPD (first hospital contact), and combined incidence [first prescription for obstructive airway disease (OAD) medication]. Annual mean concentrations of air pollutants were estimated using European-wide hybrid land-use regression models. Cox proportional hazard models were used with adjustment of demographic, socioeconomic factors, smoking, and body mass index.
3. Prophylactic noninvasive ventilation after extubation in high-risk patients without hypercapnia.
In 829 high-risk extubated patients without hypercapnia, alternating prophylactic NIV with HFNC reduced day-7 reintubation from 17.6% to 11.8% (absolute difference −5.8%). Benefits were consistent at 48 h, 72 h, and until ICU discharge, supported by G-computation estimates.
Impact: Refines extubation bundles by demonstrating benefit of prophylactic NIV beyond hypercapnic populations, with a clinically meaningful absolute risk reduction.
Clinical Implications: Consider alternating NIV with HFNC after extubation in high-risk patients regardless of PaCO2 to reduce reintubation; plan staffing/devices to implement protocolized prophylactic NIV.
Key Findings
- Day-7 reintubation: 11.8% with NIV+HFNC vs 17.6% with HFNC alone (absolute difference −5.8%, p=0.021).
- G-computation estimated a −5.6% reintubation risk reduction with NIV+HFNC.
- Lower reintubation with NIV+HFNC also at 48 h, 72 h, and through ICU discharge.
Methodological Strengths
- Multicenter dataset pooled from two clinical trials with predefined high-risk criteria.
- Multiple analytic approaches (crude comparisons and G-computation) showing concordant results.
Limitations
- Post hoc analysis may be subject to selection and center effects; not randomized to the analyzed strategies.
- Blinding not feasible; protocol variations across centers may influence outcomes.
Future Directions: Prospective randomized trials focusing on non-hypercapnic high-risk groups and implementation studies defining optimal NIV-HFNC cycling protocols and resource needs.
PURPOSE: The beneficial effects of prophylactic noninvasive ventilation (NIV) after extubation in patients without hypercapnia are uncertain. Our objective was to assess the effects of prophylactic NIV on reintubation among patients without hypercapnia at the time of extubation. METHODS: Post hoc analysis of two multicenter clinical trials including high-risk patients (i.e., patients older than 65 years or with underlying cardiac/respiratory disease). Our analysis focused on the 829 patients without hypercapnia (PaCO RESULTS: After extubation, 540 patients (65%) received NIV + HFNC while 289 (35%) received HFNC alone. The reintubation rate at day 7 was 11.8% [95% CI 9.4-14.8%] with NIV + HFNC versus 17.6% [95% CI 13.7-22.5%] with HFNC alone (difference, - 5.8% [95% CI - 11.2 to -0.8%]; p = 0.021). Using G-computation, NIV + HFNC was more effective than HFNC alone in reducing the risk of reintubation, with an estimated difference of - 5.6% [95% CI - 11.0 to - 0.5%]. Reintubation rates were also significantly lower with NIV + HFNC than with HFNC alone at 48 h, 72 h, and until ICU discharge.